Lung Cancer Clinical Trials

Showing 961-980 of 4,288 trials

Combination Study of Guadecitabine/ASTX727 and Pembrolizumab

NCT02998567

HyPeR is a multi-centre Phase 1 Dose Escalation Study of Guadecitabine (SGI-110)/ASTX727 a Second Generation Hypo-Methylating Agent in Combination with Pembrolizumab (MK3475) in Patients with Refractory Solid Tumours. The investigators will be investigating the safety and toxicity of the combination.

Non Small Cell Lung Cancer

Royal Marsden NHS Foundation Trust60 participantsStarted Jan 2017

Sutton, Surrey, United Kingdom • London, United Kingdom

Not Yet Recruiting

Validation of the SPOT-MAS Lung Test Using Circulating Tumor DNA for the Detection of Lung Cancer

NCT07126626

This is an observational clinical trial, aiming to evaluate the efficacy of the SPOTMAS LUNG (SML) test compared to Low dose CTScan (LDCT)/None contrast CTScan (NCCT) in two distinct risk populations: * Cohort A: To demonstrate that SML is concordant with LDCT/NCCT in general population lung cancer screening, including low-risk (LRs0-1-2), intermediate-risk (LRs3), and high-risk (LRs4) groups. * Cohort B: To validate the sensitivity and specificity of SML in the high-risk group (LRs4).

Lung DiseasesLung Cancer Screening

Gene Solutions1,184 participantsStarted Aug 2025

Ho Chi Minh City, Vietnam

RECRUITINGPhase 2

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

NCT05609578

Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation

Advanced NSCLCMetastatic Lung Cancer

Mirati Therapeutics Inc.90 participantsStarted Nov 2022

Anchorage, Alaska, United States • Glendale, Arizona, United States • Phoenix, Arizona, United States +163 more locations

Combination Study of Guadecitabine/ASTX727 and Pembrolizumab

Validation of the SPOT-MAS Lung Test Using Circulating Tumor DNA for the Detection of Lung Cancer

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

Related Searches

Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology

Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors

Female Asian Nonsmoker Screening Study

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

1st Line Durvalumab in PS 2 NSCLC Patients

Expanded Access of Sotorasib

Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Central and Ultra-Central Early-Stage Non-Small Cell Lung Cancer

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC)

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)